-
COST-UTILITY ANALYSIS OF REMOTE ISCHEMIC CONDITIONING FOR ACUTE MODERATE ISCHEMIC STROKE BASED ON THE RICAMIS TRIAL
Aug 11, 2026, 17:16 PM -
COST IMPACT OF TAFASITAMAB COMBINED WITH LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A TIME TO NEXT TREATMENT AND NUMBER NEEDED TO TREAT BASED PHARMACOECONOMIC ANALYSIS
Aug 11, 2026, 17:16 PM -
DEVELOPING INTERPRETATIVE LEVELS ON THE RASCH CONTINUUM FOR A NEEDS-BASED QUALITY OF LIFE MEASURE IN HUNTINGTON'S DISEASE
Aug 11, 2026, 17:16 PM -
COMPARATIVE STUDY OF TTO-BASED, HYBRID, AND DCE WITH DURATION VALUE SETS FOR EQ-5D-5L IN QATAR
Aug 11, 2026, 17:16 PM -
TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES IN FRANCE SINCE 202_THE MYOSOTYS STUDY
Aug 11, 2026, 17:16 PM -
INFORMATION-THRESHOLDED NETWORK META-ANALYSIS: FEASIBILITY AND IMPACT IN A MATURE EVIDENCE NETWORK
Aug 11, 2026, 17:16 PM -
ORGANIZATIONAL IMPACTS IN HEALTH TECHNOLOGY ASSESSMENT: A DECISION FRAMEWORK FOR EVIDENCE GENERATION
Aug 11, 2026, 17:16 PM -
CROSS-MARKET HTA OUTCOMES FOR GENE THERAPIES AND CAR-T CELL THERAPIES IN EU4 & UK MARKETS: A HISTORICAL REVIEW OF ACCESS PREFERENCES
Aug 11, 2026, 17:16 PM -
IMPACT OF REIMBURSEMENT POLICY CHANGES ON SGLT2 INHIBITORS UTILIZATION AND NATIONAL HEALTH FUND (NFZ) EXPENDITURE IN POLAND, 2019-2024
Aug 11, 2026, 17:16 PM -
DISPARITIES AND UNMET NEEDS IN VAGINITIS PATIENTS JOURNEY IN EUROPE AND THE UNITED STATES
Aug 11, 2026, 17:16 PM -
ADDRESSING THE TIMING OF OUT-OF-POCKET MEDICINE COSTS: EARLY FINDINGS FROM A NATIONAL PILOT IN FINLAND
Aug 11, 2026, 17:16 PM -
PREPARING FOR EU-LEVEL HTA OF MEDICAL DEVICES: IMPLICATIONS FOR THE FIRST JCA DEVICE ASSESSMENTS IN 2026
Aug 11, 2026, 17:16 PM -
INCREMENTAL TIGHTENING OF JAPAN'S DRUG PRICING SYSTEM: IMPLICATIONS OF THE FY2026 REFORM
Aug 11, 2026, 17:16 PM -
REAL-WORLD EFFECTIVENESS AND COST-EFFECTIVENESS OF PERTUZUMAB PLUS TRASTUZUMAB FOR HER2-POSITIVE ADVANCED BREAST CANCER IN CHINA
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS AND UNCERTAINTY ANALYSIS OF ADJUVANT TRASTUZUMAB DERUXTECAN VERSUS T-DM1 IN HER2-POSITIVE EARLY BREAST CANCER: AN SSMC TERTIARY ONCOLOGY CENTER, UAE HTA PATHWAY MODEL
Aug 11, 2026, 17:16 PM -
ESTIMATING THE BENEFITS OF AMBULATORY DELIVERY OF CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) THERAPY FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (B-ALL) IN THE UNITED KINGDOM (UK)
Aug 11, 2026, 17:16 PM -
INTEGRATING ENVIRONMENTAL SUSTAINABILITY INTO HEALTH TECHNOLOGY ASSESSMENT: A SCOPING REVIEW AND COMPARATIVE APPLICATION OF INTEGRATION METHODS USING AN INHALER CASE STUDY
Aug 11, 2026, 17:16 PM -
HOW TO FIND AND CONSIDER A CORE OUTCOME SET (COS) FOR HEALTH TECHNOLOGY ASSESSMENT AND CLINICAL GUIDELINES
Aug 11, 2026, 17:16 PM -
INFORMATION AND COMMUNICATION NEEDS OF DUTCH PARENTS REGARDING CHILDHOOD VACCINATION: A TARGETED LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
OPERATIONAL RESULTS OF THE DRUG PERFORMANCE EVALUATION MANAGEMENT SYSTEM OF THE HEALTH INSURANCE REVIEW AND ASSESSMENT SERVICE (HIRA) IN KOREA: FOCUSING ON DRUGS FOR RARE AND SEVERE DISEASES
Aug 11, 2026, 17:16 PM
